Enhancing the cytotoxic activity of novel targeted therapies - Is there a role for a combinatorial approach?

Current Clinical Pharmacology

Volumn 3, Issue 2, 2008, Pages 108-117

  Liu, Wai Man ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cell cycle; Combination therapy; HDAC; PI3K; Signalling inhibitors

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 7 HYDROXYSTAUROSPORINE; BCR ABL PROTEIN; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DEXAMETHASONE; FLAVOPIRIDOL; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LENALIDOMIDE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TRICHOSTATIN A; VORINOSTAT; WORTMANNIN; ANTINEOPLASTIC AGENT; DNA;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CELL CYCLE REGULATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON TUMOR; DNA STRUCTURE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION; CELL CYCLE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; DNA, NEOPLASM; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 52049098990     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488408784293714     Document Type: Review

References (104)

1. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
2. Sawyers CL. Research on resistance to cancer drug Gleevec. Science 2001; 294: 1834-1843.
3. Sawyers C. Targeted cancer therapy. Nature 2004; 432: 294-297.
4. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21: 309-318.
5. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17: 2941-2953.
6. Blagosklonny MV. Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 2004; 23: 2967-2975.
7. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062-1074.
8. Huang P, Oliff A. Signalling pathways in apoptosis as potential targets for cancer therapy. Trends Cell Biol 2001; 11: 343-348.
9. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy Mol Cancer Ther 2002; 1: 913-922.
10. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5: 810-816.
11. Boula A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64: 252-261.
12. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17: 3631-3652.
13. Sarker D, Evans T, Judson IJ. CHIR-258: preliminary data from a first in human phase 1 dose escalating trial of an oral, selectively targeted receptor tyrosine kinase inhibitor in patients with solid tumors. Proc Amer Soc Clin Oncol 2005; 78: 348.
14. Gorre ME, Mohammed M, Ellwood K, et al, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
15. Liu WM, te Poele RH. Recent advances and developments in the inhibitors of DNA topoisomerases. Curr Enzyme Inhib 2007; 3: 161-174.
16. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004; 3: 1001-1010.
17. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001; 11: 22-26.
18. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-1828.
19. Nurse P. Ordering S phase and M phase in the cell cycle. Cell 1994; 79: 547-550.
20. Lam EW, La Thangue NB. DP and E2F proteins: coordinating transcription with cell cycle progression. Curr Opin Cell Biol 1994; 6: 859-866.
21. Murray AW. Creative blocks: cell-cycle checkpoints and feedback controls. Nature 1992; 359: 599-604.
22. Morgan DO. Principles of CDK regulation. Nature 1995; 374: 131-1134.
23. el-Deiry WS, Tokino T, Velculescu VE, et al. A potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
24. Harper JW, Adami GR, Wei N, Keyomarsi, K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
25. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 1992; 11: 3995-4005.
26. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704.
27. Dulic V, Kaufmann WK, Wilson SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76: 1013-1023.
28. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-578.
29. Zeng YX, el-Deiry WS. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 1996; 12: 1557-1564.
30. Wang J, Walsh K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 1996; 273: 359-361.
31. Li Y, Dowbenko D, Lasky LA. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 2002; 277: 11352-11361.
32. Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer 2006; 6: 459-471.
33. Senderowicz AM, Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 1999; 17: 313-320.
34. Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des 2000; 6: 379-392.
35. Zhai S, Senderowicz AM, Sausville EA, Figg WD. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 2002; 36: 905-911.
36. Chao SH, Price DH, Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001; 27: 31793-31799.
37. Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002; 16: 1331-1343.
38. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002; 8: 3527-3538.
39. Takada Y, Aggarwal BB. Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 2004; 279: 4750-4759.
40. Stadler WM, Vogelzang NJ, Amato R. Flavopiridol, a novel cyclin-dependent kinase inhibitor in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 2000; 18: 371-375.
41. Shapiro GI, Supko JG, Patterson A. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001; 7: 1590-1599.
42. Schwartz GK, Ilson D, Saltz L. Phase II study of the cyclin dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001; 19: 1985-1992.
43. Tan AR, Headlee D, Messmann R. Phase I clinical and pharmacokinetic study of Flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002; 20: 4074-4082.
44. Swanton C. Cell cycle targeted therapies. Lancet Oncol 2004; 5: 27-36.
45. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997; 57: 3375-3380.
46. Schwartz GK, O'Reilly E, Ilson D. Phase I study of the cyclin dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumours. J Clin Oncol 2002; 20: 2157-2170.
47. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999; 5: 1876-1883.
48. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 1993; 53: 2081-2086.
49. Albers MW, Williams RT, Brown EJ, Tanaka A, Hall FL, Schreiber SL. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. J Biol Chem 1993; 268: 22825-22829.
50. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5: 2638-2645.
51. Datta SR, Brunet A, Greenberg, ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-2927.
52. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
53. Chang F, Steelman LS, Lee JT, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17: 1263-1293.
54. Cobb MH, Boulton TG, Robbins DJ. Extracellular signal-regulated kinases: ERKs in progress. Cell Regul 1991; 2: 965-978.
55. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999; 253: 239-254.
56. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001; 26: 657-664.
57. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114: 2903-2910.
58. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554-568.
59. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc Natl Acad Sci 1999; 96: 4240-4245.
60. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
61. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism ofaction ofsome commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
62. Stein RC. Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer 2001; 8: 237-248.
63. Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans 2004; 32: 393-396.
64. Sain N, Krishnan B, Ormerod MG, et al. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 2006; 5: 1197-1208.
65. Slamon DJ, Leyland-Jones B, Shak, S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
66. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
67. Giaccone G, Herbst RS, Manegold C, et al. in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 2004; 22: 777-784.
68. Herbst RS, Giaccone G, Schiller JH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 2004; 22: 785-794.
69. Ropero S, Menendez JA, Vazquez-Martin A, et al. Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 2004; 86: 125-137.
70. Brehm A, Miska EA, McCance DJ, et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998; 391: 597-601.
71. Ferreira R, Magnaghi-Jaulin L, Robin P. Proc Natl Acad Sci 1998; 95: 10493-10498.
72. Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress transcription. Cell 1998; 92: 463-473.
73. Magnaghi-Jaulin L, Groisman R, Naguibneva I, et al. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 1998; 391: 601-605.
74. Fischle W, Dequiedt F, Fillion M, et al. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 2001; 276: 35826-35835.
75. Remiszewski SW. Recent advances in the discovery of small molecule histone deacetlase inhibitors. Curr Opin Drug Discov Dev 2005; 5: 487-499.
76. Kristeleit R, Stimson L, Workman P, Aherne W. Histone modification enzymes: novel targets for cancer drugs. Expert Opin Emerg Drugs 2004; 9: 135-154.
77. Atadja P, Gao L, Kwon P, et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVPLAQ824. Cancer Res 2004; 64: 689-695.
78. Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003; 2: 721-728.
79. Yu C, Subler M, Rahmani M, et al. Induction of apoptosis in BCR/ ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biol Ther 2003; 2: 544-551.
80. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-76.
81. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105: 1768-1776.
82. Vrana JA, Decker RH, Johnson CR, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999; 18: 7016-7025.
83. Achenbach TV, Muller R, Slater EP. Bcl-2 independence of flavopiridol induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. J Biol Chem 2000; 275: 32089-32097.
84. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 2005; 25: 1608-1619.
85. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
86. Chobanian NH, Greenberg VL, Gass JM, Desimone CP, Van Nagell, JR, Zimmer SG. Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status. Anticancer Res 2004; 24: 539-545.
87. Dowdy SC, Jiang S, Zhou XC, et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006; 5: 2767-2776.
88. Kasman L, Lu P, Voelkel-Johnson C. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther 2007; 14: 327-34.
89. Zhang X, Yashiro M, Ren J, Hirakawa K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 2006; 16: 563-568.
90. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
91. Yancopoulos GD, Davis S, Gale NW, et al, Vascular-specific growth factors and blood vessel formation. Nature 2000; 40: 242-248.
92. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660.
93. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936.
94. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974.
95. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-684.
96. Strieter RM. Masters of angiogenesis. Nat Med 2005; 11: 925-927.
97. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-443.
98. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18.
99. Galustian C, Labarthe, MC, Bartlett JB, Dalgleish AG. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther 2004; 4: 1963-1970.
100. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314-322.
101. Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs 2006; 11: 635-650.
102. Lyseng-Williamson KA, Robinson DM. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs 2006; 20; 193-195.
103. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003; 2: 1011-1021.
104. Richly H, Henning BF, Kupsch P, et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006; 17: 866-873.